Business Daily from THE HINDU group of publications
Thursday, August 13, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Subscription

Group Sites

Update at 1415 hrs (IST)


Corporate
Orchid gets USFDA nod for migraine drug

MUMBAI: Drug firm Orchid Chemicals & Pharmaceuticals on Thursday said it has received final US regulatory approval for its drug Sumatriptan Succinate tablets used for the treatment of migraine attacks.

The company has received final US Food and Drug Administration (USFDA) approval, Orchid Chemicals said in a filing to the Bombay Stock Exchange. The approval of Sumatriptan Succinate tablets are in the strengths of 25 mg, 50 mg and 100 mg. - PTI

Prev: Rupee falls by 21 paise
Next: Gold rises on better global cues

Business Line | NUS Index |

Related Topics
Alliances & Joint Ventures
Announcements
Auditing
Awards & Honours
Bonus Announcements
Company Law
Corporate Bonds
Corporate Disputes
Corporate Governance
Courts/Legal Issues
Diversification
Environment
Human Resources
Interview
IPOs
IPR
Management
Mergers & Acquisitions
New Projects
Open Offers
Outlook
Outsourcing
Overseas Borrowings
Overseas Investments
People
Performance
Preferential Allotments
Private Placement
Regulatory Bodies & Rulings
Research & Development
Restructuring
Rights Issue
Sick Units
Society & Development
Standards & Benchmarks
Taxation
Trade & Labour Unions
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright copy; 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line